Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, the responses to ICI treatment are highly variable in different individuals and the underlying mechanisms remain poorly understood. Here, we employed a mouse squamous cell carcinoma (SCC) model where tumor-bearing rec...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Jessy, Chen, Samantha M. Y., Woolaver, Rachel A., Ge, Huaibin, Vashisht, Monika, Huang, Ziyu, Chen, Zhangguo, Wang, Jing H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084475/
https://www.ncbi.nlm.nih.gov/pubmed/37051229
http://dx.doi.org/10.3389/fimmu.2023.1100520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084475/
https://www.ncbi.nlm.nih.gov/pubmed/37051229
http://dx.doi.org/10.3389/fimmu.2023.1100520

Ejemplares similares